Considerations for successful cancer immunotherapy in aged hosts

Area of Science:

• Immunology
• Oncology
• Gerontology

Background:

• Cancer immunotherapy is highly successful, yet preclinical models predominantly use young subjects, neglecting aging's impact.
• Aging is the primary risk factor for cancer, highlighting a critical gap in understanding age-related immune responses to cancer and therapy.
• Current research overlooks how age-specific immune alterations, termed age-related immune dysfunction (ARID), affect cancer immune surveillance and treatment outcomes.

Purpose of the Study:

• To review age-associated changes in immunity relevant to cancer immune surveillance, pathogenesis, and immunotherapy response.
• To explore challenges and successful strategies for developing cancer immunotherapies in aged populations.
• To identify key developments and future research directions for optimizing immunotherapy in elderly cancer patients.

Main Methods:

• Literature review focusing on age-related changes in immune cell function and the tumor microenvironment.
• Analysis of how specific age-associated immune shifts, such as increased pro-inflammatory cytokines and suppressive cells, influence cancer progression.
• Examination of distinct drug effects on aged immune cells and the aged microenvironment's role as a therapeutic barrier.

Main Results:

• Immune functions do not merely decline with age but undergo detrimental changes, including the rise of pro-inflammatory and suppressive cell populations.
• Age-related immune dysfunction (ARID) presents unique challenges, affecting T-cell function, immune cell populations, drug efficacy, and the tumor microenvironment.
• Despite challenges, successful approaches to overcome age-related hurdles in cancer immunotherapy have been identified.

Conclusions:

• Age-related immune dysfunction (ARID) significantly impacts cancer immunity and immunotherapy efficacy, necessitating tailored approaches for older patients.
• Understanding and addressing ARID is crucial for advancing cancer immunotherapy in the growing elderly population.
• Further research is needed to fully elucidate ARID's mechanisms and develop effective, age-specific cancer immunotherapies.